Our group recently demonstrated that compared with healthy controls and patients with other inflammatory neurological diseases, the expression and activity of IDO1 and ARG1 in MS patients are significantly reduced, mainly in monocytes, and, to a minor degree in Trig cells and Th1 (87). The gene discussed is IDO1; the disease is myeloid sarcoma.